The correlation of serum IL-12B expression with disease activity in patients with inflammatory bowel disease

Hye Won Lee, Sook Hee Chung, Chang Mo Moon, Xiumei Che, Seung Won Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Jae Hee Cheon

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Genetic variants in IL12B, encoding the p40 subunit common in interleukin-12 (IL-12) and interleukin-23, were identified as the susceptibility loci for inflammatory bowel disease (IBD). This study aimed to identify the correlation of serum IL-12B expression with disease activity in patients with IBD and evaluate the possibility of IL-12B as a biomarker for assessing inflammatory status in IBD. A total of 102 patients with IBD, including 38, 32, and 32 patients with Crohn's disease (CD), ulcerative colitis (UC), and intestinal Behçet's disease (intestinal BD), respectively, were included. The clinical and laboratory data from the patients were collected at the time of serum IL-12B measurement. Serum IL-12B levels were measured using an enzyme-linked immunosorbent assay. The median IL-12B levels in patients with CD, UC, and intestinal BD were significantly higher than those in controls (1.87, 2.74, and 2.73 pg/mL, respectively, vs. 1.42 pg/mL, all P<0.05). IL-12B concentrations were associated with disease activity in patients with UC and intestinal BD but not in those with CD. IL-12B levels were increased with increasing disease activity in patients with UC (P<0.001). Likewise, patients with active intestinal BD had higher IL-12B levels than those without active disease (P=0.008). IL-12B levels were correlated with the endoscopic disease activity of UC (P=0.002) and intestinal BD (P=0.001) but not that of CD. Serum IL-12B levels were significantly correlated with clinical and endoscopic disease activity in patients with UC and intestinal BD, suggesting its potential use as a biomarker for assessing disease activity in these patients.

Original languageEnglish
Article numbere3772
JournalMedicine (United States)
Volume95
Issue number23
DOIs
Publication statusPublished - 2016 Jan 1

Fingerprint

Inflammatory Bowel Diseases
Intestinal Diseases
Ulcerative Colitis
Serum
Crohn Disease
Biomarkers
Interleukin-23
Interleukin-12
Enzyme-Linked Immunosorbent Assay

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Hye Won ; Chung, Sook Hee ; Moon, Chang Mo ; Che, Xiumei ; Kim, Seung Won ; Park, Soo Jung ; Hong, Sung Pil ; Kim, Tae Il ; Kim, Won Ho ; Cheon, Jae Hee. / The correlation of serum IL-12B expression with disease activity in patients with inflammatory bowel disease. In: Medicine (United States). 2016 ; Vol. 95, No. 23.
@article{62645db8b4134085baf4d5c135c31f1b,
title = "The correlation of serum IL-12B expression with disease activity in patients with inflammatory bowel disease",
abstract = "Genetic variants in IL12B, encoding the p40 subunit common in interleukin-12 (IL-12) and interleukin-23, were identified as the susceptibility loci for inflammatory bowel disease (IBD). This study aimed to identify the correlation of serum IL-12B expression with disease activity in patients with IBD and evaluate the possibility of IL-12B as a biomarker for assessing inflammatory status in IBD. A total of 102 patients with IBD, including 38, 32, and 32 patients with Crohn's disease (CD), ulcerative colitis (UC), and intestinal Beh{\cc}et's disease (intestinal BD), respectively, were included. The clinical and laboratory data from the patients were collected at the time of serum IL-12B measurement. Serum IL-12B levels were measured using an enzyme-linked immunosorbent assay. The median IL-12B levels in patients with CD, UC, and intestinal BD were significantly higher than those in controls (1.87, 2.74, and 2.73 pg/mL, respectively, vs. 1.42 pg/mL, all P<0.05). IL-12B concentrations were associated with disease activity in patients with UC and intestinal BD but not in those with CD. IL-12B levels were increased with increasing disease activity in patients with UC (P<0.001). Likewise, patients with active intestinal BD had higher IL-12B levels than those without active disease (P=0.008). IL-12B levels were correlated with the endoscopic disease activity of UC (P=0.002) and intestinal BD (P=0.001) but not that of CD. Serum IL-12B levels were significantly correlated with clinical and endoscopic disease activity in patients with UC and intestinal BD, suggesting its potential use as a biomarker for assessing disease activity in these patients.",
author = "Lee, {Hye Won} and Chung, {Sook Hee} and Moon, {Chang Mo} and Xiumei Che and Kim, {Seung Won} and Park, {Soo Jung} and Hong, {Sung Pil} and Kim, {Tae Il} and Kim, {Won Ho} and Cheon, {Jae Hee}",
year = "2016",
month = "1",
day = "1",
doi = "10.1097/MD.0000000000003772",
language = "English",
volume = "95",
journal = "Medicine (United States)",
issn = "0025-7974",
publisher = "Lippincott Williams and Wilkins",
number = "23",

}

The correlation of serum IL-12B expression with disease activity in patients with inflammatory bowel disease. / Lee, Hye Won; Chung, Sook Hee; Moon, Chang Mo; Che, Xiumei; Kim, Seung Won; Park, Soo Jung; Hong, Sung Pil; Kim, Tae Il; Kim, Won Ho; Cheon, Jae Hee.

In: Medicine (United States), Vol. 95, No. 23, e3772, 01.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The correlation of serum IL-12B expression with disease activity in patients with inflammatory bowel disease

AU - Lee, Hye Won

AU - Chung, Sook Hee

AU - Moon, Chang Mo

AU - Che, Xiumei

AU - Kim, Seung Won

AU - Park, Soo Jung

AU - Hong, Sung Pil

AU - Kim, Tae Il

AU - Kim, Won Ho

AU - Cheon, Jae Hee

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Genetic variants in IL12B, encoding the p40 subunit common in interleukin-12 (IL-12) and interleukin-23, were identified as the susceptibility loci for inflammatory bowel disease (IBD). This study aimed to identify the correlation of serum IL-12B expression with disease activity in patients with IBD and evaluate the possibility of IL-12B as a biomarker for assessing inflammatory status in IBD. A total of 102 patients with IBD, including 38, 32, and 32 patients with Crohn's disease (CD), ulcerative colitis (UC), and intestinal Behçet's disease (intestinal BD), respectively, were included. The clinical and laboratory data from the patients were collected at the time of serum IL-12B measurement. Serum IL-12B levels were measured using an enzyme-linked immunosorbent assay. The median IL-12B levels in patients with CD, UC, and intestinal BD were significantly higher than those in controls (1.87, 2.74, and 2.73 pg/mL, respectively, vs. 1.42 pg/mL, all P<0.05). IL-12B concentrations were associated with disease activity in patients with UC and intestinal BD but not in those with CD. IL-12B levels were increased with increasing disease activity in patients with UC (P<0.001). Likewise, patients with active intestinal BD had higher IL-12B levels than those without active disease (P=0.008). IL-12B levels were correlated with the endoscopic disease activity of UC (P=0.002) and intestinal BD (P=0.001) but not that of CD. Serum IL-12B levels were significantly correlated with clinical and endoscopic disease activity in patients with UC and intestinal BD, suggesting its potential use as a biomarker for assessing disease activity in these patients.

AB - Genetic variants in IL12B, encoding the p40 subunit common in interleukin-12 (IL-12) and interleukin-23, were identified as the susceptibility loci for inflammatory bowel disease (IBD). This study aimed to identify the correlation of serum IL-12B expression with disease activity in patients with IBD and evaluate the possibility of IL-12B as a biomarker for assessing inflammatory status in IBD. A total of 102 patients with IBD, including 38, 32, and 32 patients with Crohn's disease (CD), ulcerative colitis (UC), and intestinal Behçet's disease (intestinal BD), respectively, were included. The clinical and laboratory data from the patients were collected at the time of serum IL-12B measurement. Serum IL-12B levels were measured using an enzyme-linked immunosorbent assay. The median IL-12B levels in patients with CD, UC, and intestinal BD were significantly higher than those in controls (1.87, 2.74, and 2.73 pg/mL, respectively, vs. 1.42 pg/mL, all P<0.05). IL-12B concentrations were associated with disease activity in patients with UC and intestinal BD but not in those with CD. IL-12B levels were increased with increasing disease activity in patients with UC (P<0.001). Likewise, patients with active intestinal BD had higher IL-12B levels than those without active disease (P=0.008). IL-12B levels were correlated with the endoscopic disease activity of UC (P=0.002) and intestinal BD (P=0.001) but not that of CD. Serum IL-12B levels were significantly correlated with clinical and endoscopic disease activity in patients with UC and intestinal BD, suggesting its potential use as a biomarker for assessing disease activity in these patients.

UR - http://www.scopus.com/inward/record.url?scp=84975479531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975479531&partnerID=8YFLogxK

U2 - 10.1097/MD.0000000000003772

DO - 10.1097/MD.0000000000003772

M3 - Article

C2 - 27281077

AN - SCOPUS:84975479531

VL - 95

JO - Medicine (United States)

JF - Medicine (United States)

SN - 0025-7974

IS - 23

M1 - e3772

ER -